Rep. Byron Donalds Sells Novo Nordisk A/S (NYSE:NVO) Stock

Representative Byron Donalds (R-Florida) recently sold shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on April 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on March 20th.

Representative Byron Donalds also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of DoorDash NASDAQ: DASH on 3/20/2025.
• Sold $1,001 - $15,000 in shares of GoDaddy NYSE: GDDY on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of Arista Networks NYSE: ANET on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Robinhood Markets NASDAQ: HOOD on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Gartner NYSE: IT on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of Chipotle Mexican Grill NYSE: CMG on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Equifax NYSE: EFX on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of Tradeweb Markets NASDAQ: TW on 3/20/2025.
• Sold $1,001 - $15,000 in shares of JPMorgan Chase & Co. NYSE: JPM on 3/20/2025.

Novo Nordisk A/S Stock Down 7.8 %

Shares of NVO stock traded down $4.89 on Friday, hitting $57.99. The stock had a trading volume of 32,192,935 shares, compared to its average volume of 5,975,692. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a market cap of $260.23 billion, a PE ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.61. The business has a 50 day moving average price of $75.52 and a 200 day moving average price of $91.71. Novo Nordisk A/S has a one year low of $57.28 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were issued a $0.7874 dividend. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is currently 49.54%.

Wall Street Analyst Weigh In

NVO has been the subject of several research analyst reports. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, BNP Paribas assumed coverage on Novo Nordisk A/S in a research report on Tuesday. They issued an "underperform" rating for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $135.00.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors have recently made changes to their positions in NVO. Passumpsic Savings Bank raised its holdings in shares of Novo Nordisk A/S by 0.9% during the 3rd quarter. Passumpsic Savings Bank now owns 21,448 shares of the company's stock worth $2,554,000 after acquiring an additional 194 shares during the period. Virtu Financial LLC raised its stake in Novo Nordisk A/S by 69.8% during the third quarter. Virtu Financial LLC now owns 33,929 shares of the company's stock worth $4,040,000 after purchasing an additional 13,949 shares during the period. Tudor Financial Inc. acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at about $311,000. Anchor Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 2.3% in the 3rd quarter. Anchor Investment Management LLC now owns 13,447 shares of the company's stock valued at $1,601,000 after buying an additional 297 shares during the period. Finally, World Investment Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 36.9% during the 3rd quarter. World Investment Advisors LLC now owns 13,925 shares of the company's stock worth $1,655,000 after buying an additional 3,750 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida's 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida's 19th Congressional District. He declared candidacy for the 2026 election. Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor's degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.